Related by context. All words. (Click for frequent words.) 64 pancreatic gastric 63 recurrent squamous cell carcinoma 61 carcinomas 60 HNSCC 59 esophageal cancers 59 Proxinium TM 59 pancreatic adenocarcinoma 59 pancreatic prostate 59 agency carcinogen classifications 59 squamous cell cancer 59 ovarian pancreatic 58 gastric adenocarcinoma 58 receiving chemoradiation therapy 58 neck receiving ERBITUX 58 papillary renal cell carcinoma 58 nonmetastatic 58 recurrent metastatic 58 Vincent Cogliano 58 metachronous 58 colorectal lung 58 squamous cell carcinoma 58 pancreatic colon 57 Alessandro Riva 57 metastatic pancreatic 57 nodal metastasis 57 metastatic colorectal 57 nonsmall cell lung cancer 57 pancreatic carcinoma 57 thymoma 57 gastric carcinoma 57 metastatic basal cell 57 squamous cell lung cancer 57 EGFR expressing 57 gastric cancers 57 chemoradiotherapy 57 ovarian lung 57 prostate pancreatic 57 pancreatic lung 57 metastatic gastric 57 gastrointestinal cancers 57 lymphatic tissue 57 metastatic breast 56 precursor lesions 56 ADVEXIN therapy 56 colorectal ovarian 56 neoplasia 56 metastatic malignant 56 nasopharyngeal carcinoma 56 hepatocellular cancer 56 colorectal adenocarcinoma 56 SCCHN 56 uveal melanoma 56 HER2 positive cancers 56 resectable 56 ductal carcinomas 56 gastroesophageal junction 56 Vicinium TM 56 prostate carcinoma 56 distant metastasis 56 metastatic bladder 56 malignant pleural mesothelioma 56 medically inoperable 56 carcinoma 55 Glioblastoma Multiforme GBM 55 squamous cell 55 urothelial carcinoma 55 kidney urologic 55 neoadjuvant therapy 55 histopathologic examination 55 NMIBC 55 basal cell carcinoma BCC 55 HER2 positive metastatic breast 55 Li Fraumeni Syndrome 55 nonmelanoma skin cancers 55 premalignant lesions 55 renal carcinoma 55 pancreatic colorectal 55 oropharyngeal cancer 55 metastatic carcinoma 55 cervical lymph nodes 55 squamous cell cancers 55 carcinoma HCC 55 CYT# potent vascular disrupting 55 differentiated thyroid 55 squamous cell carcinoma SCC 55 leiomyomas 55 cirrhosis liver failure 55 recurrent glioblastoma multiforme 55 histological subtype 55 KRAS mutations occur 55 platinum refractory 55 pancreatic ovarian 55 breast pancreatic 55 clinically localized prostate 54 sentinel lymph node biopsy 54 GISTs 54 non squamous NSCLC 54 neoplasias 54 prostate cancer CaP 54 Hepatocellular Carcinoma HCC 54 fallopian tube carcinoma 54 colorectal carcinoma 54 intraepithelial neoplasia 54 ovarian breast 54 premalignant 54 lung pancreatic 54 cutaneous melanoma 54 epithelial ovarian 54 metastatic GIST 54 liver metastasis 54 malignant neoplasm 54 hematologic malignancies 54 liver resection 54 Papillary 54 meningiomas 54 endometrial hyperplasia 54 cytoreductive surgery 54 mesotheliomas 54 grade cervical intraepithelial 54 axilla 54 carcinoid tumors 54 ADPKD 53 histologic subtype 53 cancer mCRC 53 metastatic 53 Surgical resection 53 acute leukemias 53 ovarian carcinoma 53 bladder ovarian 53 advanced epithelial ovarian 53 cervical carcinoma 53 malignant neoplasms 53 squamous carcinoma 53 neoplastic lesions 53 adenomatous 53 metastatic liver 53 malignant lymphoma 53 BRCA deficient 53 palliative radiotherapy 53 invasive candidiasis 53 soft tissue sarcomas 53 epithelial tumors 53 pheochromocytoma 53 carcinoid tumor 53 immunohistochemical staining 53 glioblastoma multiforme GBM 53 anti angiogenic therapy 53 colorectal 53 recurrent malignant glioma 53 locoregional 53 unresectable tumors 53 mucinous 53 bladder tumors 53 TNF blocker therapy 53 colorectal cancer CRC 53 skeletal metastases 53 hypervascular tumors 53 radiolabeled TM# 53 advanced adenomas 53 metastatic squamous cell carcinoma 53 neoadjuvant treatment 53 transitional cell carcinoma 53 axillary lymph nodes 53 sorafenib tablets 53 malignant pancreatic 52 EGFR mutation positive 52 papillary 52 EGFR mutation 52 Pemetrexed 52 contralateral breast 52 neoplasm 52 squamous cell carcinomas 52 endometrial cancers 52 depsipeptide 52 gastrointestinal stromal tumors GIST 52 renal cell carcinoma 52 Chronic lymphocytic leukemia 52 prostate cancer CRPC 52 sentinel lymph node 52 recurrent glioblastoma 52 invasive carcinoma 52 Hurthle cell 52 underarm lymph nodes 52 bladder cancers 52 KRAS mutation 52 radiochemotherapy 52 Metastatic 52 BCG refractory 52 metastatic malignant melanoma 52 intestinal metaplasia 52 chromosomal mutations 52 recurrent NSCLC 52 follicular lymphoma FL 52 Glioblastoma multiforme 52 colorectal pancreatic 52 completely resected 52 metastatic lesions 52 histological subtypes 52 hormone receptor negative 52 IRX 2 52 liver metastases 52 leiomyosarcoma 52 essential thrombocythemia 52 CIN3 52 lymph node metastasis 52 malignant growths 52 lung carcinomas 52 squamous non 52 metastatic renal cell 52 lung metastasis 52 neuroendocrine carcinoma 52 renal cell carcinomas 52 gemcitabine chemotherapy 52 stage IIIb IV 52 esophagogastric junction 52 situ LCIS 52 peritoneal cancer 52 stage IIIB 52 Nicole Onetto MD 52 anaplastic 52 basal cell skin 52 symptomatic BPH 52 lenalidomide Revlimid R 52 Amrubicin 52 axillary lymph node dissection 52 Adjuvant chemotherapy 52 zalutumumab 52 pain palliation 52 chemoembolization 52 IL# PE#QQR 52 candidemia 52 nasopharyngeal cancer 52 BRCA mutation carriers 52 recurrent prostate cancer 52 cell carcinomas 52 chronic myeloid 52 metastatic lung cancer 52 extracranial 51 situ CIS 51 locoregional recurrence 51 sentinel node 51 adrenocortical cancer 51 lymphadenectomy 51 castration resistant 51 adenomatous polyps 51 Glioblastoma Multiforme 51 mRCC 51 malignant ascites 51 HBeAg negative 51 epithelial cancers 51 axitinib 51 KRAS wild 51 invasive ductal 51 node metastases 51 BRIM2 51 stage IIIB IV 51 colorectal tumors 51 Radical prostatectomy 51 papillary carcinoma 51 ductal adenocarcinoma 51 lung colorectal 51 SLNB 51 osteoid osteoma 51 pancreatic cancers 51 parathyroid carcinoma 51 EUS FNA 51 PNET 51 photodynamic treatment 51 gastrointestinal stromal tumor 51 breast carcinoma 51 squamous histology 51 brain metastases 51 refractory colorectal cancer 51 paragangliomas 51 chemoresistant 51 HER2 positive breast cancer 51 HRPC 51 carboplatin paclitaxel 51 cell carcinoma 51 CMV disease 51 Advexin 51 MALT lymphoma 51 operable breast cancer 51 LHRH receptor positive 51 hamartomas 51 antitumor effect 51 myeloproliferative disorders 51 metastases 51 ependymoma 51 Cholangiocarcinoma 51 adenoid cystic carcinoma 51 lymphoma subtypes 51 eribulin mesylate 51 Xelox 51 HER2 overexpression 51 EGFR pathway 51 Medullary thyroid cancer 51 PSADT 51 myelofibrosis polycythemia vera 51 hepatocellular carcinoma HCC 51 gastric cancer 51 cetuximab Erbitux 51 pituitary adenomas 51 metastatic HER2 positive 51 cytoreduction 51 non alcoholic steatohepatitis 51 Glioblastoma multiforme GBM 51 lymph node metastases 51 lymphoma myeloma 51 ELACYT 51 KRAS status 51 Immunohistochemical staining 51 unresectable 51 Folfox 51 carcinoid 50 TTF Therapy 50 paraganglioma 50 Toxicities 50 BRAF V#E mutation 50 prognostic variables 50 bone metastasis 50 bronchogenic carcinoma 50 pleomorphic 50 AEG# 50 Aplidin 50 CIN2 + 50 epithelioid 50 superficial bladder cancer 50 malignant ovarian 50 pre malignant lesions 50 non metastatic osteosarcoma 50 LBH# 50 Cotara R 50 NSCLC 50 advanced hepatocellular carcinoma 50 hypopharynx 50 Allovectin 7 ® 50 gefitinib Iressa 50 Lymph node 50 osteosarcomas 50 squamous 50 malignant prostate 50 resected 50 distant metastases 50 Cotara ® 50 ductal breast cancer 50 HuMax EGFr 50 stage IIIA 50 allogeneic bone marrow 50 prognostic indicator 50 lobular carcinoma 50 mycosis fungoides 50 Metastatic colorectal cancer 50 irinotecan chemotherapy 50 overlapping toxicities 50 IV NSCLC 50 epithelial origin 50 para aortic 50 metastatic colorectal cancer 50 mCRC 50 recurrent glioblastoma multiforme GBM 50 proliferative diabetic retinopathy 50 malignancies 50 hepatoma 50 telomerase inhibition 50 intravesical therapy 50 receptor tyrosine kinase inhibitor 50 benign neoplasms 50 axillary dissection 50 pancreatic 50 prostate adenocarcinoma 50 tumors GIST 50 sorafenib Nexavar 50 haematologic malignancies 50 adenocarcinomas 50 Renal Cell Carcinoma RCC 50 castrate resistant 50 pT2 50 pulmonary metastases 50 fibrotic disease 50 metastatic cancers 50 metaplasia 50 colorectal gastric 50 diagnose coronary artery 50 postoperative pathology 50 follicular thyroid cancer 50 histologically confirmed 50 metastatic relapsed 50 phase IIb study 50 myeloproliferative neoplasms 50 small lymphocytic lymphoma 50 gemcitabine carboplatin 50 gastrointestinal stromal tumors 50 tumoral 50 cell lung cancer 50 peritoneal carcinomatosis 50 Dr Valerie Delpech 50 biliary tract cancer 50 anthracycline taxane 50 localized renal 50 minimally symptomatic 50 Stage IIIb 50 Carcinoma 50 prostate cancer mCRPC 50 seminoma 50 metastatic renal cell carcinoma 50 OPAXIO 50 p# mutations 50 castrate resistant prostate cancer 50 systemic fungal infections 50 neuroendocrine cancers 50 non squamous 50 ELOXATIN 50 lung malignant melanoma 50 ductal 50 vulvar intraepithelial neoplasia 50 lung adenocarcinomas 50 urothelial cancer 50 cabazitaxel 50 metastatic adenocarcinoma 50 hyperplastic 50 mCRC patients 50 sentinel nodes 50 radiofrequency ablation RFA 50 Afatinib 50 Steven Galson MD 50 syngeneic 50 hepatocellular carcinomas 50 lung metastases 50 Ceflatonin 50 postoperative chemotherapy 50 metastatic ovarian cancer 50 subependymal giant cell 50 invasive lobular carcinoma 50 assessing T DM1 49 lymph node involvement 49 hepatocellular carcinoma 49 refractory ovarian cancer 49 trastuzumab Herceptin ® 49 Genasense ® 49 lymphovascular invasion 49 angiosarcoma 49 nodal metastases 49 systemic ALCL 49 adenoma 49 biochemical recurrence 49 paclitaxel carboplatin 49 HER2 positive 49 Virulizin ® 49 refractory CTCL 49 thalidomide Thalomid 49 Richard Pazdur 49 atypical Hemolytic Uremic Syndrome 49 metastatic disease 49 breast ovarian 49 rectal cancers 49 Metastases 49 metastatic prostate cancer 49 Vandetanib 49 surgically resectable 49 pancreatic islet cell 49 Nexavar sorafenib 49 metastatic neuroendocrine tumors 49 pertuzumab 49 cholangiocarcinoma 49 metastatic RCC 49 Evoltra ® 49 Kit CD# positive 49 histopathologic 49 chemotherapy cisplatin 49 cisplatin resistant 49 basal cell cancer 49 micrometastasis 49 advanced unresectable 49 Stephen Huhn 49 estramustine 49 resistant hormone refractory 49 mycophenolate mofetil 49 EOquin TM 49 Peginterferon alfa 2b 49 Sezary syndrome 49 recurrent ovarian 49 TTR amyloidosis 49 Lung transplantation 49 gastrointestinal stromal tumor GIST 49 CIN2 49 Cloretazine R 49 chemotherapeutic regimen 49 ADVEXIN 49 extracapsular extension 49 Jeffrey H. Buchalter 49 pleural mesothelioma 49 K ras mutations 49 phase IIb clinical 49 histologically 49 AA amyloidosis 49 medullary thyroid cancer 49 Gorlin syndrome 49 squamous cell histology 49 factor receptor EGFR 49 Metastatic breast cancer 49 atypical hyperplasia 49 seliciclib 49 MAGE A3 ASCI 49 castration resistant prostate cancer 49 chemoradiation 49 Cloretazine 49 cisplatin chemotherapy 49 Tavocept 49 relapsed leukemia 49 grade gliomas 49 cediranib 49 clinicopathological features 49 refractory metastatic colorectal cancer 49 BCIRG 49 Jeffrey Schlom 49 sarcomas 49 Exherin TM 49 Velcade bortezomib 49 seminal vesicle 49 forodesine 49 EGFR TKI 49 taxane therapy 49 renal tumors 49 malignant transformation 49 IV malignant melanoma 49 chemopreventive agent 49 curative resection 49 leukemia AML 49 histologic 49 endometrial adenocarcinoma 49 LRP5 49 intraductal 49 atherosclerotic lesions 49 bile duct tumors 49 TEMODAL 49 unresectable stage 49 tumor resection 49 prostate cancer HRPC 49 bladder carcinoma 49 opioid induced constipation OIC 49 liposomal doxorubicin 49 novel tubulin binding 48 metastatic hormone refractory 48 pT3 48 sentinel lymph nodes 48 Neoadjuvant 48 microsphere therapy 48 occult metastases 48 radiation sensitizer 48 Brain metastases 48 tumor subtypes 48 neuroendocrine tumors 48 PCa 48 neoadjuvant chemotherapy 48 neuroblastoma tumors 48 sunitinib malate 48 lung ovarian 48 BRAF inhibitor 48 Professor Jacques Donnez 48 malignant fibrous histiocytoma 48 standard chemotherapy regimen 48 basal cell carcinomas 48 relapsed multiple myeloma 48 hepatic metastases 48 bone metastases 48 Cutaneous T 48 fallopian tube cancers 48 refractory metastatic 48 radical nephrectomy 48 unresectable liver cancer 48 ErbB2 positive 48 relapsed ovarian cancer 48 Xanafide 48 Gleevec resistant 48 serous ovarian cancer 48 LUX Lung 48 lymphoid malignancies 48 prostate cancers 48 astrocytoma 48 carcinoids 48 FOLFOX6 48 neoplasms 48 docetaxel Taxotere ® 48 oral ridaforolimus 48 xenograft models 48 untreated metastatic melanoma 48 androgen independent 48 ZACTIMA 48 histologic subtypes 48 acute GvHD 48 NSCLC tumors 48 malignancy 48 cancerous enlargement 48 Cytoxan 48 leukemia ALL 48 cancers 48 acute myelogenous leukemia AML 48 antiproliferative effects 48 indolent NHL 48 GIST tumors 48 chronic HCV 48 TORISEL 48 lung prostate 48 poorer prognosis 48 Fatty Liver Clinic 48 Metastatic Colorectal Cancer 48 evaluating picoplatin 48 FOLFOX4 48 tumor lysis syndrome 48 HER2 amplification 48 sodium thiosulfate STS 48 pomalidomide 48 lung tumors 48 lymphangiogenesis 48 metastatic prostate 48 urothelial 48 uterine myoma 48 panobinostat 48 samalizumab 48 metastasis 48 lymphoid tissue 48 Taxotere R 48 IMA# 48 colorectal breast 48 hyperplastic polyps 48 neurofibromas 48 sarcomatoid 48 metastatic colon cancer 48 fine needle aspiration 48 pCR 48 glufosfamide 48 Zivadinov 48 Circulating tumor cells 48 Annamycin 48 Phase #b/#a clinical 48 malignant lesions 48 prostate cancer PCa 48 acyclovir Lauriad R 48 bevacizumab Avastin ® 48 transthyretin amyloidosis 48 tesmilifene 48 relapsed refractory multiple myeloma 48 histologies 48 epithelial ovarian cancer 48 heavily pretreated 48 Seliciclib 48 Irinotecan 48 Histopathologic examination 48 Carfilzomib 48 ixabepilone 48 Adenocarcinoma 48 Idiopathic Pulmonary Fibrosis 48 Gil Mor 48 polypoid 48 tumor necrosis 48 colorectal liver metastases 48 radical prostatectomy RP 48 cell carcinoma RCC 48 HER2 positive tumors 48 hormone receptor positive 48 PSMA ADC 48 Trastuzumab 48 adjuvant radiotherapy 48 PANVAC VF 48 relapsed SCLC 48 Pirfenidone 48 leiomyoma 48 breast carcinomas 48 BRAF mutation 48 HER2 receptor 48 Immunohistochemical analysis 48 gastric atrophy 47 gastrointestinal stromal tumors GISTs 47 alkylating agent 47 lung cancers 47 neoplastic cells 47 hypereosinophilic syndrome 47 lymphomas 47 lymphadenopathy 47 cerebrospinal fluid CSF 47 malignant polyps 47 urothelial bladder cancer 47 hormone refractory prostate cancer 47 pheochromocytomas 47 preoperative chemotherapy 47 cervical lesions 47 BRIM3 47 metastatic colorectal carcinoma 47 cytologically confirmed 47 submucosa 47 FVIII inhibitors 47 cutaneous squamous cell carcinoma 47 metastatic cancer 47 breast cancer metastasis 47 doublet chemotherapy 47 esophageal carcinoma 47 lymphocytosis 47 dacarbazine chemotherapy 47 Paul Stoffels 47 elacytarabine 47 Cloretazine ® 47 ToGA 47 thymic carcinoma 47 interferon ribavirin 47 tumor xenograft models 47 metastatic tumors 47 enzastaurin 47 lesions 47 HER2 + 47 colon esophageal 47 metastatic HRPC 47 adjuvant radiation 47 pegylated liposomal doxorubicin 47 FDG PET 47 cetuximab 47 non resectable 47 lymph node 47 talabostat 47 progesterone receptor negative 47 neoplastic 47 concurrent chemoradiation 47 Apaziquone 47 renal pelvis 47 liposomal amphotericin B 47 rectal cancer 47 mutated KRAS gene 47 cancerous lesions 47 CINTREDEKIN BESUDOTOX 47 tyrosine kinase inhibitors TKIs 47 chondrosarcoma 47 PDX pralatrexate 47 axillary node 47 synovial tissue 47 EGFR expressing mCRC 47 micrometastases 47 invasive bladder 47 IMC A# 47 heterozygous FH 47 refractory chronic lymphocytic 47 ACTEMRA TM 47 Ozarelix 47 mutant KRAS 47 malignant pheochromocytoma 47 cutaneous T cell 47 tumors 47 PROSTVAC ® 47 GNAQ 47 lymphoid 47 Erbitux cetuximab 47 curable cancers 47 plus gemcitabine 47 SJIA 47 morphologic 47 lymphocytic leukemia 47 EGFr 47 IV metastatic melanoma 47 multiple myeloma MM 47 micafungin 47 unresectable locally advanced 47 cell lymphoma CTCL 47 mapatumumab 47 refractory indolent non 47 Aflibercept 47 EGFR mutations 47 EFAPROXYN 47 hematological cancers 47 prostate breast 47 thyroid carcinoma 47 Philip Mease 47 5-FU/LV 47 androgen deprivation 47 lung nodules 47 YONDELIS 47 biochemical relapse 47 mitomycin C 47 metastatic uveal melanoma 47 PI3K Akt 47 FOLOTYN ® 47 carcinoembryonic antigen 47 tumor metastases 47 Waldenstrom macroglobulinemia 47 sunitinib Sutent 47 relapsed refractory 47 metastatic castrate resistant 47 actinic keratosis 47 sorafenib Nexavar ® 47 FGFR2 47 ERBB2 47 VNP#M 46 docetaxel Taxotere R 46 malignant cancerous 46 extranodal 46 Lenalidomide 46 Taxotere ® 46 blood clot dissolving 46 pancreatic NET 46 huN# DM1 46 gemcitabine Gemzar 46 CA4P 46 vinca alkaloid 46 dasatinib Sprycel ® 46 metastatic kidney 46 radiosensitive 46 follicular lymphoma 46 osteoblastic 46 hormone refractory 46 axillary lymph node 46 multicentric 46 adecatumumab 46 vinca alkaloids 46 luteinizing hormone releasing 46 colorectal cancer 46 stage IIIb 46 metastatic breast cancer 46 colorectal tumor 46 pazopanib 46 phase Ib 46 evaluating tivozanib 46 diabetic nephropathy 46 Torisel 46 glioblastoma 46 erlotinib Tarceva ® 46 Onyx Pharmaceuticals Announces 46 prognostic marker 46 lymphoid organs 46 metastatic lesion 46 vandetanib 46 lymph node dissection 46 metastatic castration resistant 46 adjuvant therapy 46 GBM tumors 46 familial amyloidotic polyneuropathy FAP 46 corneal graft 46 heavily pretreated patients 46 VFEND 46 XELOX 46 refractory acute myeloid 46 pharmacologic stress 46 FLT3 46 neratinib 46 hematologic disorders 46 dasatinib Sprycel 46 FOLFIRI 46 BLP# Liposome Vaccine 46 myelodysplastic syndromes 46 refractory chronic myeloid 46 KRAS mutant 46 lymphoma CTCL 46 liposarcoma 46 PNP inhibitor 46 anti inflammatory NSAID 46 dysplastic 46 colon carcinoma 46 KRAS mutant tumors 46 Zybrestat 46 FOLFOX chemotherapy 46 tumorigenicity 46 underwent prostate biopsy 46 advanced metastatic renal 46 microtubule inhibitor 46 HDACi 46 cytotoxic chemotherapy 46 refractory prostate cancer 46 huC# DM4 46 monoclonal antibody conjugated 46 multicenter Phase II 46 Quinamed 46 refractory multiple myeloma 46 lobular carcinomas 46 ALCL 46 ThermoDox R 46 NF kB pathway 46 Vectibix 46 HER2 negative 46 imatinib Gleevec ® 46 hepatitis C HCV 46 chemotherapy docetaxel 46 Samuel Wickline 46 phase IIb trial 46 Halaven 46 IGF IR 46 synovial sarcoma 46 extrahepatic 46 Fludara ® 46 activin 46 orthotopic 46 MLL AF9 46 Patrick Vallance 46 soft tissue sarcoma 46 thyroid cancers 46 anti EGFR antibody 46 olaparib 46 imatinib resistant 46 adenocarcinoma 46 intratumoral 46 SPINK1 46 E cadherin expression 46 Carcinoid tumors 46 lung cancer NSCLC 46 SIR Spheres 46 T#I [002] 46 Azedra 46 standard chemotherapy regimens 46 Dr. Andreas Tzakis 46 gemcitabine Gemzar ® 45 recurrent ovarian cancer 45 BR.# 45 renal fibrosis 45 alvespimycin 45 GIST 45 ISEL 45 BRAF V# mutation 45 vismodegib 45 noninvasive outpatient 45 WallFlex Biliary RX 45 biliary cancer 45 eosinophilic asthma 45 estrogen receptor ER 45 HCV infection 45 lymph nodes 45 bendamustine 45 cystectomy 45 lymphoid cells 45 obatoclax 45 cetuximab Erbitux R 45 CD# expressing 45 imatinib Gleevec 45 ASA# 45 xenograft tumors 45 recurrent bladder 45 CYC# 45 IV melanoma 45 pro angiogenic 45 grade dysplasia 45 localized prostate cancer 45 EpCAM 45 radiosensitivity 45 allogeneic stem cell 45 Skin grafting 45 lung adenocarcinoma 45 neoadjuvant 45 grade glioma 45 Axitinib 45 metastatic CRC 45 hypermethylation 45 leukaemias 45 metastatic medullary thyroid 45 haematological malignancies 45 recurrent GBM 45 advanced SCCHN 45 alpha folate receptor 45 Immunosuppressive 45 pan HDAC inhibitor 45 antitumor activity 45 anaplastic thyroid carcinoma 45 Troxatyl 45 mediastinal 45 Doxil ® 45 dasatinib 45 WT1 45 regorafenib 45 tumor recurrence 45 Tarceva TM 45 OncoVEX GM CSF 45 transgene expression 45 Dr. Francesco Rubino 45 endometrial 45 Clot busting 45 fluoropyrimidine 45 aflibercept 45 EGFR receptor 45 Smac mimetic 45 Cell Lung Cancer 45 fluorouracil 45 retroperitoneal 45 Steven Galson MD MPH 45 NewYork-Presbyterian/Columbia 45 Cancer Immunobiology Center 45 Phase Ib II 45 metastatic tumor 45 Dr. Klaus Stöhr 45 myeloproliferative diseases 45 Tumours 45 ALND 45 pelvic lymph nodes 45 melanoma skin 45 ganetespib 45 Radiation Therapy SIRT 45 systemic lupus erythematosus SLE 45 AVASTIN 45 refractory NSCLC 45 Massimo Napolitano 45 relapsed CLL 45 pathologic 45 scintigraphic 45 trastuzumab Herceptin R 45 oncological indications 45 c MYC